A sulindac analogue is effective against malignant pleural effusion in mice

Area of Science:

• Oncology
• Pharmacology
• Angiogenesis Research

Background:

• Malignant pleural effusion (MPE) is a common complication of various cancers, significantly impacting patient prognosis and quality of life.
• Anti-angiogenic agents are being explored for their potential to manage cancer progression and associated effusions.
• A sulindac derivative, C-18, has demonstrated anti-angiogenic properties in prior studies.

Purpose of the Study:

• To investigate the efficacy of C-18 in limiting the formation of malignant pleural effusion (MPE) in a preclinical mouse model.
• To assess the impact of C-18 on tumor dissemination within the pleural space.
• To elucidate the mechanism by which C-18 might affect MPE, focusing on vascular permeability and angiogenesis.

Main Methods:

• MPE was induced in C57BL/6 mice via intrapleural injection of murine adenocarcinoma cells.
• Mice received daily intraperitoneal doses of either 1 mg or 2 mg of C-18, or a placebo, for 12 days.
• Pleural fluid volume, tumor implantation counts, pleural vascular permeability, tumor angiogenesis, and host inflammatory response were evaluated.

Main Results:

• C-18 treatment significantly reduced pleural fluid volume in a dose-dependent manner compared to controls (p<0.001 for high dose).
• The number of intrapleural tumor implants was significantly decreased in C-18 treated groups (p=0.009 for high dose).
• C-18 effectively suppressed pleural vascular permeability, but did not significantly alter tumor angiogenesis or the inflammatory response.

Conclusions:

• The sulindac derivative C-18 demonstrates significant efficacy in halting experimental MPE formation and reducing intrapleural tumor spread in mice.
• The anti-MPE effect of C-18 is primarily mediated through the down-regulation of pleural vascular permeability.
• C-18 represents a promising therapeutic candidate for managing malignant pleural effusions.